



## **AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference**

November 16, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 16, 2023-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35<sup>th</sup> Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at <https://ir.allovir.com>.

### **About AlloVir**

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit [www.allovir.com](http://www.allovir.com) or follow us on [Twitter/X](#) or [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231116711808/en/): <https://www.businesswire.com/news/home/20231116711808/en/>

### **Media and Investor:**

[ir@allovir.com](mailto:ir@allovir.com)

Source: AlloVir, Inc.